Risk assessment of hepatotoxicity among tuberculosis and human immunodeficiency virus/AIDS-coinfected patients under tuberculosis treatment | Zendy

Williams Ngouleun | Zendy; Prosper Cabral Biapa Nya | Zendy; Constant Anatole Pieme | Zendy; Phélix Bruno Téléfo | Zendy

Open Access

Risk assessment of hepatotoxicity among tuberculosis and human immunodeficiency virus/AIDS-coinfected patients under tuberculosis treatment

Author(s) -

Williams Ngouleun,

Prosper Cabral Biapa Nya,

Constant Anatole Pieme,

Phélix Bruno Téléfo

Publication year - 2016

Publication title -

international journal of mycobacteriology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.53

H-Index - 20

eISSN - 2212-554X

pISSN - 2212-5531

DOI - 10.1016/j.ijmyco.2016.05.003

Subject(s) - medicine , tuberculosis , pyrazinamide , rifampicin , mycobacterium tuberculosis , nausea , vomiting , isoniazid , ethambutol , hepatitis , gastroenterology , immunology , pathology

Tuberculosis (TB) is a worldwide public health problem. It is a contagious and grave disease caused by Mycobacterium tuberculosis. Current drugs such as isoniazid, pyrazinamide, and rifampicin used for the treatment of tuberculosis are potentially hepatotoxic and can lead to drug hepatitis. In order to improve the follow-up of TB patients in Cameroon, we carried out a study which aimed to evaluate the hepatotoxicity risk factors associated with anti-TB drugs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research